Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec (DE:EVT)
XETRA:EVT
Holding DE:EVT?
Track your performance easily
EVT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.06 - €21.69
Previous Close€8.41
Volume263.29K
Average Volume (3M)1.71M
Market Cap
€1.49B
Enterprise Value€887.01M
Total Cash (Recent Filing)€604.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 27, 2025EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding176,952,653
10 Day Avg. Volume1,072,081
30 Day Avg. Volume1,712,375
Standard Deviation0.13
R-Squared0.03
Alpha-0.00431
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.42
Price to Sales (P/S)6.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.10Price Target Upside6.15% Upside
Rating ConsensusHold
Number of Analyst Covering4
Evotec News
Bulls Say, Bears Say
Bulls Say
Business DevelopmentPotential upside exists upon business recovery and as focus assets shift to later stages of development.
Cost ManagementEvotec has already started to reduce its footprint and teased additional divestments of non-core assets, reiterating its sustainable yearly savings target of EUR 40m.
Partnership And RevenueSandoz agreed to develop another two biosimilars with Evotec and has agreed to do commercial manufacturing for the entire biosimilar portfolio, removing a significant element of uncertainty and securing commercial revenues for J.POD 2 for the period after 2030.
Bears Say
Financial Performance ChallengesThe net debt leverage ratio reached 4.3x, partly due to worsening EBITDA, indicating additional net debt reduction is needed.
Guidance ReductionEvotec has cut its guidance from low double-digit percentage sales growth and around EUR 100m adj. EBITDA to sales of EUR 790-820m and adj. EBITDA of EUR 15-35m.
Market Recovery UncertaintyEvotec's strategic reset is expected to take time, with lingering uncertainty over when the market will recover.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.12% Insiders
8.65% Mutual Funds
<0.01% Other Institutional Investors
84.99% Public Companies and
Individual Investors
EVT FAQ
What was Evotec’s price range in the past 12 months?
Evotec lowest stock price was €5.06 and its highest was €21.69 in the past 12 months.
What is Evotec’s market cap?
Currently, no data Available
When is Evotec’s upcoming earnings report date?
Evotec’s upcoming earnings report date is Mar 27, 2025 which is in 89 days.
How were Evotec’s earnings last quarter?
Evotec released its earnings results on Nov 06, 2024. The company reported -€0.22 earnings per share for the quarter, missing the consensus estimate of -€0.11 by -€0.11.
Is Evotec overvalued?
According to Wall Street analysts Evotec’s price is currently Undervalued.
Does Evotec pay dividends?
Evotec does not currently pay dividends.
What is Evotec’s EPS estimate?
Evotec’s EPS estimate is -€0.07.
How many shares outstanding does Evotec have?
Evotec has 177,553,450 shares outstanding.
What happened to Evotec’s price movement after its last earnings report?
Evotec reported an EPS of -€0.22 in its last earnings report, missing expectations of -€0.11. Following the earnings report the stock price went down -15.294%.
Which hedge fund is a major shareholder of Evotec?
Currently, no hedge funds are holding shares in DE:EVT
---
Evotec Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-16.25%
Trailing 12-Months
Asset Growth
-11.70%
Trailing 12-Months
Company Description
Evotec
Evotec SE is a drug discovery partnership company providing drug discovery solutions to pharmaceutical and biotechnology companies, academic institutions as well as foundations and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes and complications of diabetics, pain and inflammation, oncology and infectious diseases. Its business segments are EVT execute and EVT Innovate. The EVT execute provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of the revenue is generated from the EVT execute segment.
---
EVT Stock 12 Month Forecast
Average Price Target
€9.10
▲(6.15% Upside)
Technical Analysis
Evotec
―
Faron Pharmaceuticals Oy
―
Scancell Holdings
―
OptiBiotix Health
―
Synairgen
―
Best Analysts Covering EVT
1 Year
1 Year Success Rate
12/22 ratings generated profit
1 Year Average Return
+2.06%
reiterated a sell rating last month
Copying Falko Friedrichs's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +2.06% per trade.
---